Walter V Klemp Moleculin Biotech, Inc. (MBRX) insider trading activity

Walter V Klemp is CEO and President of Moleculin Biotech, Inc.. Currently has a direct ownership of 743,607 shares of MBRX, which is worth approximately $230,518. The most recent transaction as insider was on Jun 23, 2025, when has been sold 675,675 shares (Common Stock) at a price of $0.37 per share, resulting in proceeds of $249,999. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 744K

1203.77% 3M change

1220.96% 12M change

Total Value Held $230,518

WALTER V KLEMP Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 23 2025	BUY Open market or private purchase	$249,999 $0.37 p/Share	675,675 Added 47.61%	743,607 Common Stock
Jun 22 2025	SELL Payment of exercise price or tax liability	$591 $0.27 p/Share	2,190 Reduced 3.12%	67,932 Common Stock
Jun 22 2025	BUY Exercise of conversion of derivative security	-	8,990 Added 11.36%	70,122 Common Stock
Jun 20 2025	SELL Payment of exercise price or tax liability	$246 $0.27 p/Share	914 Reduced 1.47%	61,132 Common Stock
Jun 20 2025	BUY Exercise of conversion of derivative security	-	3,750 Added 5.7%	62,046 Common Stock
Jun 16 2025	SELL Payment of exercise price or tax liability	$280 $0.69 p/Share	406 Reduced 0.69%	58,296 Common Stock
Jun 16 2025	BUY Exercise of conversion of derivative security	-	1,667 Added 2.76%	58,702 Common Stock
Jul 02 2024	SELL Payment of exercise price or tax liability	$856 $3.57 p/Share	240 Reduced 0.42%	57,035 Common Stock
Jul 02 2024	BUY Exercise of conversion of derivative security	-	982 Added 1.69%	57,275 Common Stock
Jun 22 2024	SELL Payment of exercise price or tax liability	$8,190 $3.74 p/Share	2,190 Reduced 3.74%	56,293 Common Stock
Jun 22 2024	BUY Exercise of conversion of derivative security	-	8,990 Added 13.32%	58,483 Common Stock
Jun 20 2024	SELL Payment of exercise price or tax liability	$3,454 $3.78 p/Share	914 Reduced 1.81%	49,493 Common Stock
Jun 20 2024	BUY Exercise of conversion of derivative security	-	3,750 Added 6.92%	50,407 Common Stock
Jun 16 2024	SELL Payment of exercise price or tax liability	$1,680 $4.14 p/Share	406 Reduced 0.86%	46,657 Common Stock
Jun 16 2024	BUY Exercise of conversion of derivative security	-	1,667 Added 3.42%	47,063 Common Stock
Dec 26 2023	BUY Open market or private purchase	$129,998 $0.69 p/Share	188,404 Added 21.67%	680,880 Common Stock
Jul 11 2023	SELL Payment of exercise price or tax liability	$1,897 $0.59 p/Share	3,216 Reduced 0.65%	492,476 Common Stock
Jul 11 2023	BUY Exercise of conversion of derivative security	-	13,204 Added 2.59%	495,692 Common Stock
Jul 02 2023	SELL Payment of exercise price or tax liability	$2,078 $0.58 p/Share	3,584 Reduced 0.74%	482,488 Common Stock
Jul 02 2023	BUY Exercise of conversion of derivative security	-	14,717 Added 2.94%	486,072 Common Stock
Jun 20 2023	SELL Payment of exercise price or tax liability	$7,807 $0.57 p/Share	13,697 Reduced 2.82%	471,355 Common Stock
Jun 20 2023	BUY Exercise of conversion of derivative security	-	56,250 Added 10.39%	485,052 Common Stock
Jun 16 2023	SELL Payment of exercise price or tax liability	$3,470 $0.57 p/Share	6,088 Reduced 1.4%	428,802 Common Stock
Jun 16 2023	BUY Exercise of conversion of derivative security	-	25,000 Added 5.44%	434,890 Common Stock
Nov 25 2022	BUY Open market or private purchase	$57,600 $1.28 p/Share	45,000 Added 9.89%	409,890 Common Stock

Also insider at

AMIX

Autonomix Medical, Inc.

Director

WVK

Walter V Klemp

CEO and President

Houston, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MBRX shares.

Notify only if

Value

Insider Trading

Get notified when an Moleculin Biotech, Inc. insider buys or sells MBRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Moleculin Biotech, Inc.

Track Activities on MBRX

Account